350 related articles for article (PubMed ID: 24047772)
21. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
22. PD-1 and PD-L1 antibodies in cancer: current status and future directions.
Balar AV; Weber JS
Cancer Immunol Immunother; 2017 May; 66(5):551-564. PubMed ID: 28213726
[TBL] [Abstract][Full Text] [Related]
23. Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.
Tan S; Chen D; Liu K; He M; Song H; Shi Y; Liu J; Zhang CW; Qi J; Yan J; Gao S; Gao GF
Protein Cell; 2016 Dec; 7(12):866-877. PubMed ID: 27815822
[TBL] [Abstract][Full Text] [Related]
24. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
Kline J; Gajewski TF
Curr Opin Investig Drugs; 2010 Dec; 11(12):1354-9. PubMed ID: 21154117
[TBL] [Abstract][Full Text] [Related]
25. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
Robert C; Soria JC; Eggermont AM
Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
[TBL] [Abstract][Full Text] [Related]
26. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
Ramsay AG
Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoints and their inhibition in cancer and infectious diseases.
Dyck L; Mills KHG
Eur J Immunol; 2017 May; 47(5):765-779. PubMed ID: 28393361
[TBL] [Abstract][Full Text] [Related]
29. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J
Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712
[TBL] [Abstract][Full Text] [Related]
30. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
Sui X; Ma J; Han W; Wang X; Fang Y; Li D; Pan H; Zhang L
Oncotarget; 2015 Aug; 6(23):19393-404. PubMed ID: 26305724
[TBL] [Abstract][Full Text] [Related]
31. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
32. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm.
Rao M; Valentini D; Dodoo E; Zumla A; Maeurer M
Int J Infect Dis; 2017 Mar; 56():221-228. PubMed ID: 28163164
[TBL] [Abstract][Full Text] [Related]
33. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
Brunner-Weinzierl MC; Rudd CE
Front Immunol; 2018; 9():2737. PubMed ID: 30542345
[TBL] [Abstract][Full Text] [Related]
34. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.
Zhao Y; Yang W; Huang Y; Cui R; Li X; Li B
Cell Physiol Biochem; 2018; 47(2):721-734. PubMed ID: 29794465
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint modulation for non-small cell lung cancer.
Soria JC; Marabelle A; Brahmer JR; Gettinger S
Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab for the treatment of cancer.
Gunturi A; McDermott DF
Expert Opin Investig Drugs; 2015 Feb; 24(2):253-60. PubMed ID: 25494679
[TBL] [Abstract][Full Text] [Related]
37. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
Wang Q; Wu X
Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
[TBL] [Abstract][Full Text] [Related]
38. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Ohaegbulam KC; Assal A; Lazar-Molnar E; Yao Y; Zang X
Trends Mol Med; 2015 Jan; 21(1):24-33. PubMed ID: 25440090
[TBL] [Abstract][Full Text] [Related]
39. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
Maute RL; Gordon SR; Mayer AT; McCracken MN; Natarajan A; Ring NG; Kimura R; Tsai JM; Manglik A; Kruse AC; Gambhir SS; Weissman IL; Ring AM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6506-14. PubMed ID: 26604307
[TBL] [Abstract][Full Text] [Related]
40. Current and Emerging Perspectives on Immunotherapy for Melanoma.
Daud A
Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
